Larocca. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
t r a n s p l a n t a t i o n . All time to events were calculated from the time of random assignment to maintenance treatment arms. Abbreviations: R, lenalidomide; RP, lenalidomide-prednisone; PFS_m, progression-free survival from the random assignment to maintenance arm; OS, overall survival from the random assignment to maintenance arm; HR, hazard ratio; CI, confidence interval; p, p value. Antithrombotic prophylaxis was mandatory: aspirin or low-molecular weight heparin or warfarin were permitted at physician's discretion.
Lenalidomide

Endpoints and assessments
The primary endpoint was progression-free survival (PFS); secondary endpoints included response rate, time to the first evidence of response, overall survival (OS), and incidence of grade ≥3 adverse events (AEs).
Response and progression were assessed after each cycle during induction and then every 6 to 8 weeks until PD. After PD was confirmed, patients were followed every 90 days to document subsequent treatment and survival status. All time to events were calculated from the time of random assignment to induction arm for the analysis on induction treatment. All time to events in the analysis of maintenance treatment were calculated from the random assignment to maintenance arm. PFS was calculated from the time of random assignments until the date of progression, relapse, death as a result of any cause, or the date the patient was last known to be in remission. Time to next treatment (TNT, post-hoc analysis) was calculated from the time of random assignments until the date the subsequent myeloma therapy was administered at progression or relapse, the date of death from any cause, or the date the patient was last known to be in remission. Progression-free survival 2 (PFS-2, post-hoc analysis) was calculated from the time of random assignments until the date of second progression or death for any cause or the date the patient was last known to be alive. PFS-2 was evaluated in order to detect possible negative effects of a maintenance-containing first-line treatment on the subsequent line of therapy. 1 OS was calculated from the time of random assignments until the date of death for any cause or the date the patient was last known to be alive. The response to treatment was defined by using International Uniform Response Criteria. 2 All AEs were assessed at each visit and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (v3.0). 3 
Statistical analysis: supplementary information
